Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 5/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14295176 | 0.88 | ALDH1A1 (0.54) | POLBTACR2KMT2AALDH1A1HPGD | |
| SCHEMBL684440 | 0.79 | GPR142 (0.43) | TACR2ACACB | |
| SCHEMBL10266645 | 0.79 | ALDH1A1 (0.54) | TACR2KMT2AALDH1A1HPGDCD274 | |
| SCHEMBL7287015 | 0.78 | TACR2 (0.54) | POLBTACR2KMT2AALDH1A1HPGD | |
| SCHEMBL681503 | 0.77 | ALDH1A1 (0.52) | POLBTACR2KMT2AALDH1A1HPGD | |
| SCHEMBL847408 | 0.70 | TACR2 (0.58) | TACR2KMT2AACACBALDH1A1CD274 | |
| SCHEMBL1512746 | 0.70 | CD274 (0.75) | POLBALDH1A1HPGDCD274 | |
| SCHEMBL24311576 | 0.70 | CYP1A2 (0.44) | ALDH1A1 | |
| SCHEMBL24311640 | 0.70 | CYP1A2 (0.44) | ALDH1A1 | |
| SCHEMBL8181698 | 0.70 | ALDH1A1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | POLB 613/4885BACE1 3292/4885TACR2 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.